palonosetron
palonosetron: sourced relationships with 2 companies · 1 clinical trial tracked · 2 FDA decisions.
palonosetron evidence translation
What we can confirm
2 FDA records · 1 tracked trial
What it means
What to watch
Prepared research question
What is verified about palonosetron, and what remains unknown?
Traceable citations · Unknowns marked
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| AKORN INC (AKRX) Reported 2015-11-09 · Current development: unknownSource | Approved |
| DR REDDYS LABORATORIES LTD (RDY) Reported 2016-04-21 · Current development: unknownSource | Approved |
Clinical Trial Registry Records (1)
A Pivotal Phase 3 Observer-Blind, Randomized Clinical Trial of the Efficacy and Safety of APF530 Compared to Aloxi For The Prevention of Acute-Onset and Delayed-Onset Chemotherapy-Induced Nausea and Vomiting Following The Administration of Either Moderately or Highly Emetogenic Chemotherapy Regimens
Primary endpoint: Proportion of Patients With Complete Response (CR) During Acute Phase (0-24 Hours) After Administration of Chemotherapy Course 1
FDA Decisions2 records
Frequently asked questions
Which companies have sourced relationships with palonosetron?
palonosetron has dated SEC/FDA relationship records for AKORN INC, DR REDDYS LABORATORIES LTD.
How many clinical trials involve palonosetron?
BioSniper tracks 1 clinical trial involving palonosetron.
What is palonosetron's latest FDA decision?
The most recent tracked FDA decision for palonosetron is Approval, dated April 21, 2016.